The decision layer for the Saudi pharma market. Which molecule to register next, when the window opens and who is moving — computed from the live SFDA register, with the evidence behind every number attached.
Built for BD, market-access & regulatory teams at pharma, biotech & generics companies — with device intelligence one click away.
One RaqibHealth engine under nine live surfaces — each built to move a decision, not to browse a table.
ALSO IN THE FAMILY · DeviceTracker (live — the full SFDA device register) · PriceBench (live — classify a product, benchmark its box price) · On the roadmap: CHCWire (cosmetics & supplements) · TenderPulse (NUPCO & MoH tenders) · ShelfWatch (e-pharmacy shelves) · DistroWatch (distribution graph).
Not a slow consultancy report. Not a generic SaaS dashboard. A precise tool for a specific market.
Every answer traces to its SFDA register — the drug register synced hourly and every register self-auditing, with a freshness board that alarms us before you ever see stale data. The engine is the product; the plumbing is the warranty.
AI reads every drug record — originator, therapy area, strategic flag. Then ask it anything: Ask RaqibHealth answers in plain English, grounded in the live registry.
Drugs approved abroad but not yet in KSA, Saudi trials, and US patent cliffs that open generic windows — ranked, with entry windows from the measured FDA → SFDA lag.
The complete SFDA drug register — every brand, pack, price and agent — cross-matched with US FDA, EMA and Saudi clinical-trial data.
Arabic source records read and surfaced in English, by a team fluent in the Saudi market. Arabic UI on the roadmap.
Annual, per-organisation licensing — PO-friendly, multi-seat and ready for security review.
Regulatory data is scattered across formats, languages, and systems that keep no memory of what changed. RaqibHealth turns it into a living decision layer — current, connected, and tracked over time, ranked by what matters to your brand.
Static, siloed, raw tables no one can act on.
Dynamic, ranked, live decisions leaders can make.
No magic. Just boring, well-engineered infrastructure that runs on a clock.
16 official sources, each monitored at the right cadence — critical signals like new drug approvals and safety recalls the hour SFDA publishes them. The infrastructure is boring on purpose.
Every record is enriched into decision-ready intelligence — originator brand, therapy area, a market-impact read and a strategic flag — with a human-review backstop on lower-confidence calls.
Each subscriber’s watchlist is checked against new records. Matches trigger email alerts within the hour. The Monday digest summarises the week.
Annual, per-organisation, with seats. Catching one generic wave or launch window early can defend millions in brand revenue — RaqibHealth is a fraction of that, and a fraction of the global CI suites, because it’s built only for KSA.
Founding cohort — the first 10 organisations get 40% off year one, locked for 12 months · multi-year & multi-affiliate discounts · single modules available à la carte. info@raqibhealth.com
Start with the free Pulse digest — every SFDA recall and the week’s new registrations. Founding pricing for the first teams aboard. Your competitor isn’t watching this yet — but they will.
No credit card for Pulse · talk to us at info@raqibhealth.com for a team plan.